Dual targeted therapy of biologics in inflammatory bowel disease: state-of-the-art
10.3760/cma.j.cn101480-20220318-00046
- VernacularTitle:生物制剂双靶治疗炎症性肠病的研究现状
- Author:
Jinlu TONG
1
;
Zhihua RAN
1
Author Information
1. 上海交通大学医学院附属仁济医院消化内科 上海市消化疾病研究所 上海市炎症性肠病研究中心，上海 200127
- Publication Type:Journal Article
- Keywords:
Inflammatory bowel disease;
Biologics;
Dual targeted therapy
- From:
Chinese Journal of Inflammatory Bowel Diseases
2022;06(2):106-109
- CountryChina
- Language:Chinese
-
Abstract:
More and more biologics are available in China, but the efficacy of single biologic can hardly be improved greatly. Dual targeted therapy is mainly used for additional treatment of patients who have partial response to a kind of biologic or relapse during maintenance treatment, which has become the future exploration direction of inflammatory bowel disease (IBD) treatment. This article summarizes the latest research progress of dual targeted therapy of biologics in IBD from the theoretical basis, efficacy, safety, factors to be considered and special drug type of bispecific antibody drugs.
